home / stock / alpmy / alpmy news

ALPMY News and Press, Astellas Pharma Inc. ADR From 11/14/19

Stock Information
Company Name: Astellas Pharma Inc. ADR
Stock Symbol: ALPMY
Market: OTC
Menu
ALPMY ALPMY Quote ALPMY Short ALPMY News ALPMY Articles ALPMY Message Board
Get ALPMY Alerts

News, Short Squeeze, Breakout and More Instantly...
ALPMY - Aravive - Novel Approach To Blocking GAS6-AXL Pathway That Plays Key Roles In Cancer And Fibrosis; Reverse-Merger Path Has Created Unique Opportunity

Aravive's Reverse Merger Path to Public Company Creates Potentially Compelling Overlooked and Underfollowed Investment Opportunity If a company chooses to go public through a reverse merger instead of the more conventional IPO path, it has a higher chance to become an Overlooked and Underf...
ALPMY - FibroGen down 6% despite positive roxadustat date in late-stage CKD study

A Phase 3 clinical trial, HIMALAYAS , evaluating FibroGen's ( FGEN -6% ) roxadustat in chronic kidney disease (CKD) patients who recently initiated dialysis met both primary endpoints . The data were presented at the American Society of Nephrology Kidney Week in Washington, DC. More ne...

ALPMY - New England Journal of Medicine Publishes Results from Astellas' Phase 3 ADMIRAL Trial of XOSPATA® (gilteritinib) in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia(1)

TOKYO , Oct. 31, 2019 /PRNewswire/ -- The New England Journal of Medicine published detailed results from the Phase 3 ADMIRAL trial, which found that Astellas Pharma Inc.'s (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D. "Astellas") XOSPATA ® (gilteritinib) demonstrated ...

ALPMY - U.S. FDA Grants Fast Track Designation to Astellas for the Development of ASP1128 for Patients at Risk for Acute Kidney Injury

TOKYO , Oct. 28, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of ASP1128 for patients at increased risk ...
ALPMY - Astellas' gilteritinib OK'd in Europe for type of AML

The European Commission approves Astellas Pharma's ( OTCPK:ALPMY ) XOSPATA (gilteritinib) for the treatment of adult patients with relapsed/refractory FLT3 mutation-positive acute myeloid leukemia (AML), a type of AML with a poor prognosis. More news on: Astellas Pharma Inc., Astellas Ph...

ALPMY - European Commission Approves Astellas' XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

TOKYO , Oct. 25, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") announced today that the European Commission (EC) has approved the oral once-daily therapy XOSPATA ™  (gilteritinib) as a monotherapy for the tre...

ALPMY - FibroGen: Updates To Thesis, Clinical And Regulatory Catalysts Loom

Shares of FibroGen ( FGEN ) have risen by 80% since I called the stock a Strong Buy back in 2016, noting that lead program roxadustat (a hypoxia-inducible factor-prolyl hydroxylase or HIF-PH inhibitor) offers several benefits over conventional injectable anemia treatments, including reductio...
ALPMY - Astellas Commits Nearly $13 Million to Fund Boston-Area Start-Up Innovation in Cell and Gene Therapy

TOKYO , Oct. 1, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced it will invest nearly $13 million into two innovation incubators operated by LabCentral, a premier United States -based laboratory fac...

ALPMY - Seattle Genetics surges on bladder cancer treatment results

Seattle Genetics ( SGEN +10.2% ) breaks out to an all-time high after the company and partner Astellas Pharma ( OTCPK:ALPMY ) presented "encouraging" initial results for a bladder cancer treatment. More news on: Seattle Genetics, Inc., Astellas Pharma Inc., Immunomedics, Inc., Healthca...

ALPMY - Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer

BOTHELL, Wash. and TOKYO , Sept. 28, 2019 /PRNewswire/ --  Seattle Genetics, Inc.  (Nasdaq: SGEN) and Astellas Pharma Inc.  (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced initial results from the phase 1 clinical trial EV-103. Forty-f...
Previous 10 Next 10